V Craig Jordan

Summary

Affiliation: Fox Chase Cancer Center
Country: USA

Publications

  1. ncbi request reprint Activated estrogens and antiestrogens: a 30-year journey with David Kupfer
    V Craig Jordan
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Drug Metab Rev 38:117-27. 2006
  2. ncbi request reprint The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy
    V Craig Jordan
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Breast 14:624-30. 2005
  3. pmc New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer
    V Craig Jordan
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
    Steroids 72:829-42. 2007
  4. pmc Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients
    V Craig Jordan
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Breast 16:S105-13. 2007
  5. ncbi request reprint SERMs: meeting the promise of multifunctional medicines
    V Craig Jordan
    Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    J Natl Cancer Inst 99:350-6. 2007
  6. ncbi request reprint Chemoprevention of breast cancer with selective oestrogen-receptor modulators
    V Craig Jordan
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, Pennsylvania 19111 2497, USA
    Nat Rev Cancer 7:46-53. 2007
  7. pmc Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer
    V Craig Jordan
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, United States
    Steroids 72:7-25. 2007
  8. pmc Beyond raloxifene for the prevention of osteoporosis and breast cancer
    V C Jordan
    Fox Chase Cancer Center, 333 East Cottman Avenue, Philadelphia, PA 19111, USA
    Br J Pharmacol 150:3-4. 2007
  9. ncbi request reprint Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial
    V Craig Jordan
    Fox Chase Cancer Centre, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Eur J Cancer 42:2909-13. 2006
  10. ncbi request reprint The science of selective estrogen receptor modulators: concept to clinical practice
    V Craig Jordan
    Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    Clin Cancer Res 12:5010-3. 2006

Detail Information

Publications80

  1. ncbi request reprint Activated estrogens and antiestrogens: a 30-year journey with David Kupfer
    V Craig Jordan
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Drug Metab Rev 38:117-27. 2006
    ..Tamoxifen and insecticides covalently bind to microsomal proteins. His contribution presaged worldwide studies of the induction of rat liver carcinogenesis by tamoxifen...
  2. ncbi request reprint The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy
    V Craig Jordan
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Breast 14:624-30. 2005
    ..Low-dose estrogen could be used to debulk patients followed by fulvestrant in a low estrogen environment (aromatase treatment) to maintain tumor control...
  3. pmc New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer
    V Craig Jordan
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
    Steroids 72:829-42. 2007
    ..Clearly these are particularly important issues not only for breast cancer treatment but also for selecting premenopausal women, at high risk for breast cancer, as candidates for chemoprevention using tamoxifen...
  4. pmc Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients
    V Craig Jordan
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Breast 16:S105-13. 2007
    ..Once our program is complete, the new knowledge will be available to translate to clinical care for the long-term maintenance of patients on antihormone therapy...
  5. ncbi request reprint SERMs: meeting the promise of multifunctional medicines
    V Craig Jordan
    Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    J Natl Cancer Inst 99:350-6. 2007
    ..Changes in health care strategies to implement chemoprevention take time, but the evidence now suggests that chemoprevention has become a reality in clinical practice...
  6. ncbi request reprint Chemoprevention of breast cancer with selective oestrogen-receptor modulators
    V Craig Jordan
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, Pennsylvania 19111 2497, USA
    Nat Rev Cancer 7:46-53. 2007
    ..New medicines now promise to provide chemoprevention strategies for women at risk for the development of many diseases...
  7. pmc Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer
    V Craig Jordan
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, United States
    Steroids 72:7-25. 2007
    ..Current clinical trials are addressing the value of aromatase inhibitors as chemopreventive agents for postmenopausal women...
  8. pmc Beyond raloxifene for the prevention of osteoporosis and breast cancer
    V C Jordan
    Fox Chase Cancer Center, 333 East Cottman Avenue, Philadelphia, PA 19111, USA
    Br J Pharmacol 150:3-4. 2007
    ..However, raloxifene has the beneficial side-effect of breast cancer prevention. These multifunction medicines provide proof of concept that novel molecules can be selectively targeted to diseases mediated by the endocrine system...
  9. ncbi request reprint Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial
    V Craig Jordan
    Fox Chase Cancer Centre, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Eur J Cancer 42:2909-13. 2006
    ....
  10. ncbi request reprint The science of selective estrogen receptor modulators: concept to clinical practice
    V Craig Jordan
    Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    Clin Cancer Res 12:5010-3. 2006
  11. pmc Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer
    V Craig Jordan
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
    Br J Pharmacol 147:S269-76. 2006
    ....
  12. ncbi request reprint Selective estrogen-receptor modulators and antihormonal resistance in breast cancer
    V Craig Jordan
    Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111 2497, USA
    J Clin Oncol 25:5815-24. 2007
    ..This will allow the precise treatment of diseases that was previously considered impossible...
  13. ncbi request reprint Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices--point
    V Craig Jordan
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
    Cancer Epidemiol Biomarkers Prev 16:2207-9. 2007
  14. pmc New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis
    V Craig Jordan
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Breast 18:S10-7. 2009
    ..The question to be addressed is how we can amplify the new biology of oestrogen-induced apoptosis to create more complete responses in exhaustively antihormone treated metastatic breast cancer...
  15. doi request reprint A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention
    V Craig Jordan
    Fox Chase Cancer Center, Philadelphia, Pennsylvania 9111 2497, USA
    Cancer Res 69:1243-54. 2009
    ..During the past 50 years, ideas about the value of antihormones translated effectively from the laboratory to improve clinical care, improve national survival rates, and significantly reduced the burden of cancer...
  16. ncbi request reprint The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer--survival or death?
    V Craig Jordan
    Medical Sciences, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    J Clin Oncol 26:3073-82. 2008
    ..This new discovery is currently being evaluated in clinical trials but it also solves the mystery mechanism of chemical therapy with estrogen noted by Haddow in the first Karnofsky lecture...
  17. ncbi request reprint Improvements in tumor targeting, survivorship, and chemoprevention pioneered by tamoxifen. A personal perspective
    V Craig Jordan
    Medical Science Division, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Oncology (Williston Park) 20:553-62; discussion 567-8, 573, 577. 2006
    ..This knowledge would establish a practical approach to breast cancer chemoprevention for women at high risk (tamoxifen) and low risk (raloxifene)...
  18. pmc Tamoxifen: catalyst for the change to targeted therapy
    V Craig Jordan
    Alfred G Knudson Chair of Cancer Research, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Eur J Cancer 44:30-8. 2008
    ..Currently, the pharmaceutical industry is exploiting the SERM concept for all members of the nuclear receptor superfamily so that medicines can now be developed for diseases once thought impossible...
  19. pmc Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis
    Joan S Lewis-Wambi
    Department of Medical Sciences, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Breast Cancer Res 10:R104. 2008
    ..In the present study, we evaluated whether buthionine sulfoximine (BSO), a potent inhibitor of glutathione (GSH) synthesis, is capable of sensitizing antihormone resistant MCF-7:2A cells to estradiol-induced apoptosis...
  20. pmc Emerging principles for the development of resistance to antihormonal therapy: implications for the clinical utility of fulvestrant
    Eric A Ariazi
    Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    J Steroid Biochem Mol Biol 102:128-38. 2006
    ....
  21. pmc The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells
    Eric A Ariazi
    Fox Chase Cancer Center Department of Pharmacology, Temple University School of Medicine, Philadelphia, Pennsylvania, USA
    Cancer Res 70:1184-94. 2010
    ..Further, flow cytometry showed that G-1 blocked MCF-7 cell cycle progression at the G(1) phase. Thus, GPR30 antagonizes growth of ERalpha-positive breast cancer and may represent a new target to combat this disease...
  22. pmc Potential of l-buthionine sulfoximine to enhance the apoptotic action of estradiol to reverse acquired antihormonal resistance in metastatic breast cancer
    Joan S Lewis-Wambi
    Department of Medical Sciences, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, United States
    J Steroid Biochem Mol Biol 114:33-9. 2009
    ....
  23. ncbi request reprint Optimizing the antihormonal treatment and prevention of breast cancer
    Roshani R Patel
    Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Breast Cancer 14:113-22. 2007
    ..This paper will summarize the therapeutic options for anti-hormonal therapy, the role of anti-hormonal agents in advanced breast cancer, and adjuvant therapy and the current status of chemoprevention with selective ER modulators...
  24. pmc Expression of estrogen receptor alpha with a Tet-off adenoviral system induces G0/G1 cell cycle arrest in SKBr3 breast cancer cells
    Jing Peng
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Oncol 36:451-8. 2010
    ....
  25. pmc Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?
    Joan S Lewis-Wambi
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Breast Cancer Res 11:206. 2009
    ..This finding has implications for the control of breast cancer with low-dose estrogen and other targeted therapeutic drugs...
  26. pmc Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time
    Eric A Ariazi
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Proc Natl Acad Sci U S A 108:18879-86. 2011
    ..Therefore, these data indicate that E(2) induced apoptosis through ERS and inflammatory responses in advanced antihormone-resistant breast cancer...
  27. ncbi request reprint Steroid receptors and their role in the biology and control of breast cancer growth
    Fernando Cordera
    Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Semin Oncol 33:631-41. 2006
    ..Better understanding of steroid receptors, their ligands, and the mechanisms through which they exert their effects will allow the correct treatment to be targeted to responsive tumors...
  28. pmc Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance
    Gregor M Balaburski
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Oncol 37:387-98. 2010
    ..These data and literature reports of the cyclical nature of anti-androgen/androgen responsiveness of prostate cancer growth, illustrate the generality of the evolution of anti-hormonal resistance in sex steroid-sensitive target tissues...
  29. ncbi request reprint Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs)
    Joan S Lewis-Wambi
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Breast Dis 24:93-105. 2005
    ..This review article discusses the significant and continuing value of SERMs for the treatment of postmenopausal ER-positive breast cancer...
  30. pmc Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer
    Jing Peng
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Anticancer Agents Med Chem 9:481-99. 2009
    ..Major efforts are therefore directed to make new SERMs with a better therapeutic profile and fewer side effects...
  31. pmc Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen
    Philipp Y Maximov
    Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    J Med Chem 53:3273-83. 2010
    ..Using available conformations of the ER liganded with 4OHTAM or diethylstilbestrol, the TPEs optimally occupy the 4OHTAM ER conformation that expresses Asp351...
  32. pmc Overexpression of CEACAM6 promotes migration and invasion of oestrogen-deprived breast cancer cells
    Joan S Lewis-Wambi
    Department of Medical Sciences, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Eur J Cancer 44:1770-9. 2008
    ..In conclusion, our findings establish CEACAM6 as a unique mediator of migration and invasion of drug resistant oestrogen-deprived breast cancer cells and suggest that this protein could be an important biomarker of metastasis...
  33. pmc The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1
    Joan S Lewis-Wambi
    Women s Cancer Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Mol Pharmacol 80:610-20. 2011
    ..Together, these findings indicate that BZA is distinct from other SERMs in its ability to inhibit hormone-independent breast cancer cell growth and to regulate ERα and cyclin D1 expression in resistant cells...
  34. ncbi request reprint Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation
    Joan S Lewis
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Natl Cancer Inst 97:1746-59. 2005
    ..Here, we investigated the role of the mitochondrial apoptotic pathway in this process...
  35. ncbi request reprint Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance
    Surojeet Sengupta
    Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Adv Exp Med Biol 630:206-19. 2008
    ..Another approach exploits the discovery that low dose estrogen will induce apoptosis in the SERM resistant breast cancers. Numerous clinical studies are addressing these issues...
  36. ncbi request reprint Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance
    Joan S Lewis
    Fox Chase Cancer Center, Alfred G Knudson Chair of Cancer Research, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Mutat Res 591:247-63. 2005
    ....
  37. ncbi request reprint SERMs for the treatment and prevention of breast cancer
    Ramona F Swaby
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
    Rev Endocr Metab Disord 8:229-39. 2007
    ..Overall, SERMs continue to fulfill their promise as appropriate medicines that target specific populations for the treatment and prevention of breast cancer...
  38. ncbi request reprint Estrogen receptors as therapeutic targets in breast cancer
    Eric A Ariazi
    Fox Chase Cancer Center, Philadelphia, PA 19111 2497 USA
    Curr Top Med Chem 6:181-202. 2006
    ..Crosstalk among plasma membrane-localized ER, growth factor receptor signaling, and nuclear-localized ER provide further insights into antihormonal-resistant breast cancer...
  39. doi request reprint Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer
    Ramona F Swaby
    Department of Medical Oncology Division of Medical Sciences, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Clin Breast Cancer 8:124-33. 2008
    ..When resistant cells are killed, antihormonal therapy is once again effective. This new targeted approach to the treatment of metastatic breast cancer could open the door to novel approaches to treatment with drug combinations...
  40. pmc Selective estrogen receptor modulators and phytoestrogens
    Tawakalitu Oseni
    Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Planta Med 74:1656-65. 2008
    ..This article reviews the development and role of the more common SERMs, tamoxifen and raloxifene. In addition, this paper will also highlight the emerging studies on phytoestrogens and their similarity and dissimilarity to SERMs...
  41. ncbi request reprint A STAR is born
    V Craig Jordan
    Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Oncology (Williston Park) 20:1126. 2006
  42. ncbi request reprint Estrogen-related receptors as emerging targets in cancer and metabolic disorders
    Eric A Ariazi
    Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Curr Top Med Chem 6:203-15. 2006
    ..Moreover, expression of ERRs in other cancers and metabolic disorders may provide a targeted treatment strategy for these patients as well...
  43. pmc Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells
    Jane J Yu
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Proc Natl Acad Sci U S A 106:2635-40. 2009
    ..Taken together these results reveal a new model for LAM pathogenesis in which activation of MEK-dependent pathways by E(2) leads to pulmonary metastasis via enhanced survival of detached tuberin-null cells...
  44. ncbi request reprint Chemoprevention of breast cancer: current and future prospects
    Sam G Pappas
    Department of Surgery and Molecular Pharmacology, Robert H Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, IL 60611, USA
    Cancer Metastasis Rev 21:311-21. 2002
    ..These compounds will function as multifunctional medicines and will hold the promise of preventing breast and endometrial cancer, while providing the beneficial effects of preventing osteoporosis and coronary heart disease...
  45. ncbi request reprint In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer
    Hiroyuki Takei
    Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center, USA
    Breast Cancer 9:39-42. 2002
    ..In this study we investigated the in vitro effects of antiestrogens at different concentrations on vascular endothelial growth factor (VEGF) production in estrogen receptor (ER)-positive breast cancer cells...
  46. doi request reprint The rise of raloxifene and the fall of invasive breast cancer
    V Craig Jordan
    J Natl Cancer Inst 100:831-3. 2008
  47. ncbi request reprint The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators
    Ruth M O'Regan
    Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA
    Lancet Oncol 3:207-14. 2002
    ..Furthermore, two different classes of hormonal agents, the aromatase inhibitors and oestrogen-receptor downregulators, which have no oestrogen-like properties at any site, are promising new treatments for breast cancer...
  48. pmc Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells
    Hong Liu
    Robert H Lurie Comprehensive Cancer Center and the Department of Surgery, Northwestern University Medical School, Chicago, Illinois 60611, USA
    J Biol Chem 277:9189-98. 2002
    ..Alteration of either the side chain or its relationship with the negative charge at amino acid 351 controls the estrogen-like action at activating function 2b of the selective estrogen receptor modulator ERalpha complex...
  49. ncbi request reprint Chemoprevention of breast cancer: a model for change
    V Craig Jordan
    J Clin Oncol 20:1-3. 2002
  50. ncbi request reprint Role of antiestrogens and aromatase inhibitors in breast cancer treatment
    David J Bentrem
    Department of Surgery, Robert H Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611, USA
    Curr Opin Obstet Gynecol 14:5-12. 2002
    ..Additionally, two different classes of hormonal agents, the aromatase inhibitors and estrogen receptor down-regulators, which have no estrogen-like properties at any site, appear to be promising new treatments for advanced breast cancer...
  51. ncbi request reprint Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention
    Woo Chan Park
    Lynn Sage Breast Cancer Research Program, Robert H Lurie Comprehensive Cancer Center, Olson Pavilion 8258, 303 E Chicago Avenue, Chicago, IL 60611, USA
    Trends Mol Med 8:82-8. 2002
    ..Emerging knowledge about the action of SERMs will provide clues for the design of mechanism-based medicines...
  52. ncbi request reprint The secrets of selective estrogen receptor modulation: cell-specific coregulation
    V Craig Jordan
    Robert H Lurie Comprehensive Cancer Center, The Feinberg School of Medicine, Northwestern University, 303 East Chicago Avenue, Chicago, IL 60611, USA
    Cancer Cell 1:215-7. 2002
    ..A specific increase in the level of a single coactivator appears to enhance estrogen action with tamoxifen at some gene targets in uterine cells but not breast cells...
  53. ncbi request reprint Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo
    Rita C Dardes
    Department of Gynecology, Federal University of Sao Paulo, SP, Brazil 04023 900
    Clin Cancer Res 8:1995-2001. 2002
    ..The purpose was to evaluate the effects of the new tamoxifen analogue GW5638 on breast and endometrial cancer growth...
  54. pmc A new day dawns: women without oestrogen or is a balance best?
    V Craig Jordan
    Robert H Lurie Comprehensive Cancer Center, The Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Breast Cancer Res 4:218-21. 2002
    ..It is now clear that strategies utilising aromatase inhibitors and selective oestrogen receptor modulators will provide much needed options for individualised treatments...
  55. ncbi request reprint Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade
    Csaba Gajdos
    Robert H Lurie Comprehensive Cancer Center, Northwestern University Medical School, 303 E Chicago Avenue, Chicago, IL 60611, USA
    Clin Breast Cancer 2:272-81. 2002
    ....
  56. ncbi request reprint Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice
    Ruth M O'Regan
    Division of Hematology Oncology, Northwestern University, Chicago, IL 60611, USA
    J Natl Cancer Inst 94:274-83. 2002
    ..We evaluated the effects on tumor growth of raloxifene, another SERM, after tamoxifen treatment in mouse models of breast and endometrial cancers...
  57. ncbi request reprint Tamoxifen: a most unlikely pioneering medicine
    V Craig Jordan
    The Robert H Lurie Comprehensive Cancer Center, Northwestern University Medical School, 303 East Chicago Avenue, Olson Pavilion 8258, Chicago, Illinois 60611, USA
    Nat Rev Drug Discov 2:205-13. 2003
    ..However, 40 years ago, it was hard to imagine that a non-toxic targeted treatment for breast cancer could be developed at all...
  58. ncbi request reprint Is tamoxifen the Rosetta stone for breast cancer?
    V Craig Jordan
    J Natl Cancer Inst 95:338-40. 2003
  59. ncbi request reprint Selective estrogen receptor modulation: concept and consequences in cancer
    V Craig Jordan
    Northwestern University, Chicago, IL, USA
    Cancer Cell 5:207-13. 2004
    ..The future exploitation of these novel data will allow selective killing of cancer with fewer side effects for patients...
  60. ncbi request reprint Acceptance of tamoxifen chemoprevention by physicians and women at risk
    Julia Tchou
    The Lynn Sage Breast Program, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Cancer 100:1800-6. 2004
    ..The purpose of the current study was to identify factors associated with being offered, and accepting, tamoxifen chemoprevention...
  61. ncbi request reprint The consequences of exhaustive antiestrogen therapy in breast cancer: estrogen-induced tumor cell death
    Clodia Osipo
    Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Exp Biol Med (Maywood) 229:722-31. 2004
    ..This minireview will describe the current strategies for the treatment and prevention of breast cancer and present emerging new concepts about the consequences of exhaustive antiestrogen treatment on therapeutic resistance...
  62. ncbi request reprint Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial
    Victor G Vogel
    Magee Womens Hospital, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213 3221, USA
    JAMA 295:2727-41. 2006
    ..Tamoxifen is approved for the reduction of breast cancer risk, and raloxifene has demonstrated a reduced risk of breast cancer in trials of older women with osteoporosis...
  63. ncbi request reprint Pak up your breast tumor--and grow!
    V Craig Jordan
    J Natl Cancer Inst 98:657-9. 2006
  64. ncbi request reprint Advances in endocrine therapy for the treatment and prevention of breast cancer
    William J Gradishar
    Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Cancer Chemother Biol Response Modif 21:211-22. 2003
  65. ncbi request reprint Models of hormone resistance in vitro and in vivo
    Jennifer MacGregor Schafer
    Robert H Lurie Comprehensive Cancer Center, The Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Methods Mol Med 120:453-64. 2006
    ..However, there is an evolution of drug resistance to anti-hormones. This is evidenced by a change in sensitivity to estrogen. The natural hormone no longer stimulated tumor growth but causes apoptosis and tumor regression...
  66. ncbi request reprint Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy
    Clodia Osipo
    Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    J Steroid Biochem Mol Biol 93:249-56. 2005
    ..Based on the results, we suggest using an alternating treatment regimen, cycling antiestrogen with estrogen therapy to avoid drug-resistance...
  67. ncbi request reprint Deregulation of estrogen induced telomerase activity in tamoxifen-resistant breast cancer cells
    Woo Chan Park
    Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Int J Oncol 27:1459-66. 2005
    ..We conclude that the differential regulation of telomerase gene might be an important transition for tamoxifen resistance in T47D:A18 breast cancer cells...
  68. ncbi request reprint Aromatase inhibitors that regulate estrogen target tissues selectively?
    V Craig Jordan
    Bone 34:372-5. 2004
  69. ncbi request reprint Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer
    Clodia Osipo
    Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    J Natl Cancer Inst 95:1597-608. 2003
    ..We investigated the molecular mechanism(s) of estradiol-induced tumor regression by using an in vivo model of tamoxifen-stimulated human breast cancer...
  70. ncbi request reprint Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions
    V Craig Jordan
    Robert H Lurie Comprehensive Cancer Center, The Feinberg School of Medicine of Northwestern University, 303 East Chicago Avenue, MS N505, Chicago, Illinois 60611, USA
    J Med Chem 46:883-908. 2003
  71. ncbi request reprint Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents
    V Craig Jordan
    Robert H Lurie Comprehensive Cancer Center, The Feinberg School of Medicine of Northwestern University, 303 East Chicago Avenue, MS N505, Chicago, Illinois 60611, USA
    J Med Chem 46:1081-111. 2003
  72. ncbi request reprint A mechanism of drug resistance to tamoxifen in breast cancer
    Jennifer MacGregor Schafer
    Robert H Lurie Comprehensive Cancer Center, The Feinberg School of Medicine, Northwestern University, Olson Pavilion 8258, 303 East Chicago Avenue, Chicago, IL 60611, USA
    J Steroid Biochem Mol Biol 83:75-83. 2002
    ..Three phases of tumor progression are described that involve increases in HER-2/neu expression, de-regulation of estrogen receptor expression and increases in apoptosis which in concert determine the phenotype of drug resistance to Tam...
  73. ncbi request reprint The evolving role of endocrine therapy for the treatment and prevention of breast cancer
    William J Gradishar
    Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center, 676 North St Clair Street, Suite 850, Chicago, IL 60611 2927, USA
    Cancer Chemother Biol Response Modif 20:227-38. 2002
  74. ncbi request reprint Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer
    Clodia Osipo
    Department of Pathology, Oncology Institute, Cardinal Bernadin Cancer Center, Loyola University Medical Center, Maywood, IL, USA
    Int J Oncol 30:509-20. 2007
    ....
  75. ncbi request reprint The current status of breast cancer chemoprevention: a star is born
    Monica Morrow
    J Surg Oncol 95:4-5. 2007
  76. ncbi request reprint Re: Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999
    V Craig Jordan
    J Natl Cancer Inst 95:683-4; author reply 684-5. 2003
  77. ncbi request reprint The estrogen receptor: a model for molecular medicine
    Elwood V Jensen
    Department of Cell Biology, Vontz Center for Molecular Studies, University of Cincinnati, Ohio 45267, USA
    Clin Cancer Res 9:1980-9. 2003
    ....
  78. ncbi request reprint Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo
    Hong Liu
    Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    J Natl Cancer Inst 95:1586-97. 2003
    ..We developed a raloxifene-resistant MCF-7 cell model (MCF-7/Ral) and investigated the nature of raloxifene-resistant breast cancer and its response to estradiol...
  79. ncbi request reprint Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex
    Bin Chen
    Robert H Lurie Comprehensive Cancer Center, The Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Int J Oncol 27:327-35. 2005
    ..We conclude that endogenous ERbeta may not play a dominant role in the modulation of the tamoxifen ERalpha complex, or in the development of tamoxifen-stimulated resistant tumor growth...